Announced details
Ophthalmology; limbal stem cell deficiency (LSCD)
Alliance partner. The companies have established a collaborative framework for sharing safety information on recombinant human dHGF protein and optimising the manufacturing process.
An unlisted biotech venture originating from Harvard University in the United States. It is advancing drug development of recombinant human dHGF protein in ophthalmology and conducting clinical trials in the United States for limbal stem cell deficiency and corneal scarring.
In this announcement the company addresses none of Contract Value / Offering price / Impact on Business Performance.
Claris Biotherapeutics press release (https://www.clarisbio.com/news/press-releases/09-29-2026/)
| Item | Details |
|---|---|
| Names of Products / Services Covered | CSB-001 (oremepermin alfa ophthalmic solution), Recombinant human dHGF protein |
| Counterparty | Claris Biotherapeutics |
| Counterparty overview | An unlisted biotech venture originating from Harvard University in the United States. It is advancing drug development of recombinant human dHGF protein in ophthalmology and conducting clinical trials in the United States for limbal stem cell deficiency and corneal scarring. |
| Relationship with the Company | Alliance partner. The companies have established a collaborative framework for sharing safety information on recombinant human dHGF protein and optimising the manufacturing process. |
| Launch date | October 2026 (scheduled presentation at the AAO 2026 Annual Meeting) |
| Applicable area | Ophthalmology; limbal stem cell deficiency (LSCD) |
| Source | Claris Biotherapeutics press release (https://www.clarisbio.com/news/press-releases/09-29-2026/) |
Items this document does not state (11)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Claris Biotherapeutics will present the efficacy of CSB-001 in LSCD at the AAO 2026 Annual Meeting. The company says it will strengthen its collaboration with Claris Biotherapeutics and promote the global development and commercialisation of oremepermin alfa.